about
A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndromeMedical and Behavioral Approaches to Engage People Who Inject Drugs Into Care for Hepatitis C Virus Infection.HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells.Rare birds in North America: acute hepatitis C cohortsLiver fibrosis during an outbreak of acute hepatitis C virus infection in HIV-infected men: a prospective cohort study.Shedding of Hepatitis C Virus Into the Rectum of HIV-infected Men Who Have Sex With Men.Shedding of Hepatitis C Virus in Semen of Human Immunodeficiency Virus-Infected Men.Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.Increased Mitochondrial Genetic Diversity in Persons Infected With Hepatitis C Virus.Telaprevir in the treatment of acute hepatitis C virus infection in HIV-infected men.Enhanced FCGR2A and FCGR3A signaling by HIV viremic controller IgG.The stoichiometry of binding of the herpes simplex virus type 1 origin binding protein, UL9, to OriS.Acute HCV in HIV-infected MSM: modes of acquisition, liver fibrosis, and treatment.Sofosbuvir in the treatment of early HCV infection in HIV-infected men.Acute hepatitis C outbreak among HIV-infected men, Madrid, Spain.Early-onset liver fibrosis due to primary hepatitis C virus infection is higher over time in HIV-infected men.The Order of Addition of Immunocompromise: The Effects of HIV Infection on Fibrosis Progression Among Hepatitis C Virus-Infected Patients.Defining the Scope of Sexually Transmitted Hepatitis C Virus Epidemic Among HIV-Infected Men Who Have Sex With Men in New York City.The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.Thalidomide for the treatment of AIDS-associated wastingHIV-1 dynamics in haemodialysis patientsEffects of sofosbuvir-based hepatitis C treatment on the pharmacokinetics of tenofovir in HIV/HCV-coinfected individuals receiving tenofovir disoproxil fumarateLedipasvir/Sofosbuvir for 8 Weeks to Treat Acute Hepatitis C Virus Infections in Men With Human Immunodeficiency Virus Infections: Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1 Infected IndividualsSexually Acquired Hepatitis C Infection in HIV-Uninfected Men Who Have Sex With Men Using Preexposure Prophylaxis Against HIVA serological assay to detect SARS-CoV-2 seroconversion in humans
P50
Q28267885-6ADF8775-122A-4BAA-A7F3-7393477DC684Q33853664-F8498F2A-2E00-4FC1-8A30-8F51459DDA99Q33887674-904F2174-0DCE-4A08-89F8-DEA4ED2A7C2CQ34084126-6DA2A2EF-18D2-4F97-9E15-6D42AED56196Q35904333-8B1503FA-81CE-4E07-AD66-E50E8C532F9CQ36232894-CC37D579-EACD-4C9B-A77F-B79CC92DC95CQ36900065-CD4F42F1-ABDC-4AA6-868A-374852DD32C2Q36948099-56125512-BBDA-4ECE-9F04-E6B3F09AB2DBQ37297724-27B07DF4-BF31-4010-A39C-354CAFBA542CQ37604517-EA09412A-C72C-4249-9B08-E5CB1295082BQ37646897-9A6F7ACB-7879-4245-9517-70139FA96618Q38297332-EB456699-41FC-4997-9895-A25BE5AD2586Q38543695-2C60EA7C-8781-479D-BA3C-C3D3E577FCB3Q38759266-6D455912-DFED-4EDA-9460-7A04C6AA1C59Q43039207-A411D499-C524-4860-B88B-B95C50E3DA81Q43110496-5210B825-AC1A-4038-ACD7-DBEE8FEDCC78Q45334201-E4448CBE-5C42-40ED-933F-68E941E8AEC7Q45341162-62C77C81-9E65-41B8-8660-C43210760978Q47687531-7E705BB3-9FAB-437B-B34C-8695146143DDQ73040546-92C22447-1284-47FA-8CFA-1E5B46C82E1EQ74230115-0E0351E9-E6D3-4A1A-94AC-0BCFDF83B80CQ88627916-C2AD8A05-C4C7-410D-B403-853F3D8DB46BQ92904016-CF9F35CB-4652-4C4A-BAFB-2F6C284EE78BQ93270711-04802723-A69D-4E71-B2CE-624D6F5493CAQ94600837-4F19437C-9764-4EA9-B1E9-255EA438DF3F
P50
description
researcher
@en
wetenschapper
@nl
name
Daniel S. Fierer
@en
Fierer DS
@ast
Fierer DS
@nl
type
label
Daniel S. Fierer
@en
Fierer DS
@ast
Fierer DS
@nl
altLabel
Fierer DS
@en
prefLabel
Daniel S. Fierer
@en
Fierer DS
@ast
Fierer DS
@nl
P106
P31
P496
0000-0002-3427-8022